{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T02:22:51Z","timestamp":1771899771162,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,5,4]],"date-time":"2018-05-04T00:00:00Z","timestamp":1525392000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["advancesradonc.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Radiation Oncology"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.adro.2018.04.015","type":"journal-article","created":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T13:45:44Z","timestamp":1527169544000},"page":"399-404","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Multi-institutional report on toxicities of concurrent nivolumab and radiation therapy"],"prefix":"10.1016","volume":"3","author":[{"given":"Neha P.","family":"Amin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maliha","family":"Zainib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean M.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuj","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malcolm D.","family":"Mattes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.adro.2018.04.015_bib0010","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung Cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.adro.2018.04.015_bib0015","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.adro.2018.04.015_bib0020","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.adro.2018.04.015_bib0025","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.adro.2018.04.015_bib0030","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.adro.2018.04.015_bib0035","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.adro.2018.04.015_bib0040","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1634\/theoncologist.2017-0004","article-title":"FDA approval summary: Nivolumab for the treatment of relapsed or progressive classical Hodgkin lymphoma","volume":"22","author":"Kasamon","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.adro.2018.04.015_bib0045","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): A multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.adro.2018.04.015_bib0050","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","article-title":"Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.adro.2018.04.015_bib0055","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1158\/1078-0432.CCR-14-2824","article-title":"Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions","volume":"21","author":"Filatenkov","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.adro.2018.04.015_bib0060","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1158\/0008-5472.CAN-14-1258","article-title":"Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade","volume":"74","author":"Dovedi","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.adro.2018.04.015_bib0065","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.adro.2018.04.015_bib0070","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ijrobp.2017.02.003","article-title":"Multicenter evaluation of the tolerability of combined treatment with PD-1 and CTLA-4 immune checkpoint inhibitors and palliative radiotherapy","volume":"98","author":"Bang","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2018.04.015_bib0075","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1634\/theoncologist.2016-0517","volume":"22","author":"Sharabi","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.adro.2018.04.015_bib0080","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/j.ijrobp.2015.07.136","article-title":"Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy","volume":"93","author":"Ahmed","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2018.04.015_bib0085","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: A pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2018.04.015_bib0090","doi-asserted-by":"crossref","first-page":"8910","DOI":"10.18632\/oncotarget.13315","article-title":"Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: A systematic review and meta-analysis of randomized clinical trials","volume":"8","author":"Costa","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.adro.2018.04.015_bib0095","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.adro.2018.04.015_bib0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0145936","article-title":"The response, outcome and toxicity of aggressive palliative thoracic radiotherapy for metastatic non-small cell lung cancer patients with controlled extrathoracic diseases","volume":"10","author":"Chiang","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.adro.2018.04.015_bib0105","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/02841860701621233","article-title":"Clinical benefit of palliative radiation therapy in advanced gastric cancer","volume":"47","author":"Kim","year":"2008","journal-title":"Acta Oncol"},{"key":"10.1016\/j.adro.2018.04.015_bib0110","doi-asserted-by":"crossref","DOI":"10.21037\/phe.2016.08.06","article-title":"Palliative radiotherapy","volume":"1","author":"Li","year":"2016","journal-title":"Public Health Emerg"},{"key":"10.1016\/j.adro.2018.04.015_bib0115","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/cncr.22555","article-title":"A review of hypofractionated palliative radiotherapy","volume":"109","author":"Lutz","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.adro.2018.04.015_bib0120","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.prro.2011.01.005","article-title":"Palliative thoracic radiotherapy in lung cancer: An American Society for Radiation Oncology evidence-based clinical practice guideline","volume":"1","author":"Rodrigues","year":"2011","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.adro.2018.04.015_bib0125","article-title":"Acute pancreatitis: An unexpected toxicity when combining nivolumab and stereotactic body radiation therapy [e-pub ahead of print]","author":"Amin","year":"2017","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.adro.2018.04.015_bib0130","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.adro.2018.04.015_bib0135","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ijrobp.2016.04.017","article-title":"Safety and efficacy of radiation therapy in advanced melanoma patients treated with ipilimumab","volume":"96","author":"Qin","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2018.04.015_bib0140","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1158\/2326-6066.CIR-13-0082","article-title":"Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma","volume":"1","author":"Barker","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.adro.2018.04.015_bib0145","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.ijrobp.2016.07.005","article-title":"A prospective clinical trial combining radiation therapy with systemic immunotherapy in metastatic melanoma","volume":"96","author":"Hiniker","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Advances in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109418300782?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109418300782?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:35:35Z","timestamp":1762529735000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452109418300782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S2452109418300782"],"URL":"https:\/\/doi.org\/10.1016\/j.adro.2018.04.015","relation":{},"ISSN":["2452-1094"],"issn-type":[{"value":"2452-1094","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multi-institutional report on toxicities of concurrent nivolumab and radiation therapy","name":"articletitle","label":"Article Title"},{"value":"Advances in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.adro.2018.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Author(s). Published by Elsevier Inc. on behalf of the American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}]}}